| Paul D Righi, MD | |
|
590 Court St, Cheshire Medical Center-dartmouth Hitchcock - Keene, Keene, NH 03431-1719 | |
| (603) 354-5454 | |
| Not Available |
| Full Name | Paul D Righi |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 38 Years |
| Location | 590 Court St, Keene, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629093372 | NPI | - | NPPES |
| 5305 | Other | VT | BC VT |
| 040016937 | Other | VT | RR MEDICARE |
| 30201701 | Medicaid | NH | |
| 1003204 | Other | NH | BC NH |
| 0009220 | Medicaid | VT | |
| 600772 | Other | VT | MVP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 0420007679 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cheshire Medical Center | Keene, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cheshire Medical Center | 1456260165 | 155 |
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
News Archive
A new international study of children with a severe form of acute lymphoblastic leukemia(ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survival.
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.
The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.
A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.
The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.
› Verified 3 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
A new international study of children with a severe form of acute lymphoblastic leukemia(ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survival.
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.
The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.
A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.
The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.
› Verified 3 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
A new international study of children with a severe form of acute lymphoblastic leukemia(ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survival.
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.
The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.
A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.
The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.
› Verified 3 days ago
| Entity Name | Cheshire Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093803397 PECOS PAC ID: 1456260165 Enrollment ID: O20070913000090 |
News Archive
A new international study of children with a severe form of acute lymphoblastic leukemia(ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survival.
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.
The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.
A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.
The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul D Righi, MD 590 Court Street, Keene, NH 03431-1719 Ph: (603) 354-5454 | Paul D Righi, MD 590 Court St, Cheshire Medical Center-dartmouth Hitchcock - Keene, Keene, NH 03431-1719 Ph: (603) 354-5454 |
News Archive
A new international study of children with a severe form of acute lymphoblastic leukemia(ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survival.
Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.
The Milken Institute is launching a resource to help the public and policymakers track progress in the development of treatments and vaccines for COVID-19.
A promising new compound appears to impede a process that fuels breast cancer in mice, a discovery that could have implications in the treatment of a host of cancers.
The once-daily integrase inhibitor dolutegravir has shown promise in a phase III noninferiority study comparing it with twice-daily raltegravir for treatment of HIV-1, indicate study results presented at the 19th International AIDS Conference in Washington DC, USA.
› Verified 3 days ago
Dr. Avery Nicole Nelson, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 580 Court St, North Building, Level 1a, Keene, NH 03431 Phone: 603-354-5496 Fax: 603-354-5498 | |
Dr. Donald V. Wilson, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: Dartmouth Hitchcock Clinic/keene, 590 Court St, Keene, NH 03431 Phone: 603-354-5454 |